Greenwich LifeSciences (GLSI) Competitors $9.73 -0.57 (-5.53%) Closing price 04:00 PM EasternExtended Trading$9.75 +0.02 (+0.21%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLSI vs. KURA, MNMD, DNA, URGN, ARVN, TSHA, CGEM, ETON, ALT, and SANAShould you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Kura Oncology (KURA), Mind Medicine (MindMed) (MNMD), Ginkgo Bioworks (DNA), UroGen Pharma (URGN), Arvinas (ARVN), Taysha Gene Therapies (TSHA), Cullinan Therapeutics (CGEM), Eton Pharmaceuticals (ETON), Altimmune (ALT), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Greenwich LifeSciences vs. Kura Oncology Mind Medicine (MindMed) Ginkgo Bioworks UroGen Pharma Arvinas Taysha Gene Therapies Cullinan Therapeutics Eton Pharmaceuticals Altimmune Sana Biotechnology Kura Oncology (NASDAQ:KURA) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Do analysts prefer KURA or GLSI? Kura Oncology currently has a consensus price target of $24.50, indicating a potential upside of 295.16%. Greenwich LifeSciences has a consensus price target of $39.00, indicating a potential upside of 300.82%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.93Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to KURA or GLSI? In the previous week, Kura Oncology had 17 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 18 mentions for Kura Oncology and 1 mentions for Greenwich LifeSciences. Kura Oncology's average media sentiment score of 0.53 beat Greenwich LifeSciences' score of -3.00 indicating that Kura Oncology is being referred to more favorably in the media. Company Overall Sentiment Kura Oncology Positive Greenwich LifeSciences Very Negative Is KURA or GLSI more profitable? Kura Oncology's return on equity of -44.09% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -44.09% -39.57% Greenwich LifeSciences N/A -185.12%-164.27% Do insiders & institutionals believe in KURA or GLSI? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 6.4% of Kura Oncology shares are owned by company insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer KURA or GLSI? Kura Oncology received 431 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 69.73% of users gave Kura Oncology an outperform vote while only 47.37% of users gave Greenwich LifeSciences an outperform vote. CompanyUnderperformOutperformKura OncologyOutperform Votes44069.73% Underperform Votes19130.27% Greenwich LifeSciencesOutperform Votes947.37% Underperform Votes1052.63% Which has more risk & volatility, KURA or GLSI? Kura Oncology has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Which has preferable valuation & earnings, KURA or GLSI? Greenwich LifeSciences has lower revenue, but higher earnings than Kura Oncology. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$67.99M7.89-$152.63M-$2.10-2.95Greenwich LifeSciencesN/AN/A-$8.89M-$1.20-8.11 SummaryKura Oncology beats Greenwich LifeSciences on 10 of the 17 factors compared between the two stocks. Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLSI vs. The Competition Export to ExcelMetricGreenwich LifeSciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.16M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-12.168.9226.8419.71Price / SalesN/A250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book18.716.466.794.50Net Income-$8.89M$143.98M$3.23B$248.18M7 Day Performance3.29%3.04%4.07%1.14%1 Month Performance4.18%7.44%12.52%15.20%1 Year Performance-28.14%-2.46%16.83%6.56% Greenwich LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLSIGreenwich LifeSciences1.1962 of 5 stars$9.73-5.5%$39.00+300.8%-21.3%$129.16MN/A-12.163Positive NewsEarnings ReportKURAKura Oncology4.309 of 5 stars$6.09+5.7%$23.89+292.3%-71.3%$498.67M$67.99M-2.58130News CoverageAnalyst ForecastAnalyst RevisionMNMDMind Medicine (MindMed)2.2716 of 5 stars$6.45+4.9%$25.11+289.3%-6.5%$486.12MN/A-2.8540Positive NewsDNAGinkgo Bioworks1.1138 of 5 stars$8.30+6.9%$4.58-44.9%N/A$481.62M$237.42M-0.63640Positive NewsURGNUroGen Pharma4.0658 of 5 stars$11.14+7.3%$32.86+194.9%-41.6%$478.59M$90.40M-3.54200Trending NewsGap DownTrading HaltedARVNArvinas3.7292 of 5 stars$6.52-1.4%$20.91+220.7%-80.0%$475.90M$426.90M-2.35420TSHATaysha Gene Therapies3.0279 of 5 stars$2.32+8.9%$6.63+185.6%-5.2%$475.73M$8.33M3.68180Earnings ReportAnalyst RevisionGap DownCGEMCullinan Therapeutics2.3141 of 5 stars$7.91+4.9%$32.00+304.6%-67.1%$466.81MN/A-2.7930Positive NewsGap UpETONEton Pharmaceuticals2.3951 of 5 stars$17.35+3.3%$27.67+59.5%+438.5%$465.29M$39.01M-78.8620Positive NewsAnalyst RevisionHigh Trading VolumeALTAltimmune2.6299 of 5 stars$6.01+7.5%$20.20+236.1%-27.2%$462.85M$20,000.00-3.8850News CoverageAnalyst RevisionGap UpSANASana Biotechnology2.4431 of 5 stars$2.00+9.9%$10.80+440.0%-75.8%$450.95MN/A-1.43380Gap UpHigh Trading Volume Related Companies and Tools Related Companies KURA Competitors MNMD Competitors DNA Competitors URGN Competitors ARVN Competitors TSHA Competitors CGEM Competitors ETON Competitors ALT Competitors SANA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLSI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLSI Stock Free GLSI Stock Alerts